The prevalence, clinical features, predictive factors and investigations to screen for cancer in patients with inflammatory myositis

References

1. ↵
   1. Bohan A,
   2. Peter JB

   (1975) Polymyositis and dermatomyositis (second of two parts). N Engl J Med 292:403–407.

   OpenUrlCrossRefPubMedWeb of Science
2. ↵
   1. Bohan A,
   2. Peter JB

   (1975) Polymyositis and dermatomyositis (first of two parts). N Engl J Med 292:344–347.

   OpenUrlCrossRefPubMedWeb of Science
3. ↵
   1. Buchbinder R,
   2. Hill CL

   (2002) Malignancy in patients with inflammatory myopathy. Curr Rheumatol Rep 4:415–426.

   OpenUrlCrossRefPubMed
4. ↵
   1. Al-Ballaa ST,
   2. Al-Dalaan AN,
   3. El-Ramahi KM,
   4. Al-Janadi MA,
   5. Al-Shaikh A,
   6. Bahabri S

   (1993) Pattern of adult onset of polymyositis and dermatomyositis and association with malignancy. Ann Saudi Med 13:525–529.

   OpenUrlPubMed
5. ↵
   1. Lundberg IE,
   2. Tjarnlund A,
   3. Bottai M,
   4. Werth VP,
   5. Pilkington C,
   6. Visser M,
   7. et al.

   (2017) 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann Rheum Dis 76:1955–19564.

   OpenUrlAbstract/FREE Full Text
6. ↵
   1. Mustafa KN,
   2. Al-Heresh AM,
   3. Khataybeh OY,
   4. Alawneh KM,
   5. Khader YS

   (2015) Low prevalence of malignancy in patients with idiopathic inflammatory myopathies in Jordan. Clin Exp Rheumatol 33:731–733.

   OpenUrl
7. ↵
   1. Limaye V,
   2. Luke C,
   3. Tucker G,
   4. Hill C,
   5. Lester S,
   6. Blumbergs P,
   7. et al.

   (2013) The incidence and associations of malignancy in a large cohort of patients with biopsy-determined idiopathic inflammatory myositis. Rheumatol Int 33:965–971.

   OpenUrlCrossRefPubMed
8. ↵
   1. Tang MM,
   2. Thevarajah S

   (2010) Paraneoplastic Dermatomyositis:A 12-year Retrospective Review in the Department of Dermatology Hospital Kuala Lumpur. Med J Malaysia 65:138–142.

   OpenUrl
9. ↵
   1. Azuma K,
   2. Yamada H,
   3. Ohkubo M,
   4. Yamasaki Y,
   5. Yamasaki M,
   6. Mizushima M,
   7. et al.

   (2011) Incidence and predictive factors for malignancies in 136 Japanese patients with dermatomyositis, polymyositis and clinically amyopathic dermatomyositis. Mod Rheumatol 21:178–183.

   OpenUrlCrossRefPubMed
10. ↵
    1. Kannan MA,
    2. Sundaram C,
    3. Uppin M,
    4. Mridula R,
    5. Jabeen SA,
    6. Borgohain R

    (2013) Incidence of malignancies in biopsy-proven inflammatory myopathy. Neurol India 61:152–155.

    OpenUrl
11. ↵
    1. Lee SW,
    2. Jung SY,
    3. Park MC,
    4. Park YB,
    5. Lee SK

    (2006) Malignancies in Korean patients with inflammatory myopathy. Yonsei Med J 47:519–523.

    OpenUrlPubMed
12. ↵
    1. Andras C,
    2. Ponyi A,
    3. Constantin T,
    4. Csiki Z,
    5. Szekanecz E,
    6. Szodoray P,
    7. et al.

    (2008) Dermatomyositis and polymyositis associated with malignancy:a 21-year retrospective study. J Rheumatol 35:438–444.

    OpenUrlAbstract/FREE Full Text
13. 1. Chen YJ,
    2. Wu CY,
    3. Huang YL,
    4. Wang CB,
    5. Shen JL,
    6. Chang YT

    (2010) Cancer risks of dermatomyositis and polymyositis:a nationwide cohort study in Taiwan. Arthritis Res Ther 12:R70.

    OpenUrlCrossRefPubMed
14. ↵
    1. Hill CL,
    2. Zhang Y,
    3. Sigurgeirsson B,
    4. Pukkala E,
    5. Mellemkjaer L,
    6. Airio A,
    7. et al.

    (2001) Frequency of specific cancer types in dermatomyositis and polymyositis:a population-based study. Lancet 357:96–100.

    OpenUrlCrossRefPubMedWeb of Science
15. ↵
    1. Lu X,
    2. Yang H,
    3. Shu X,
    4. Chen F,
    5. Zhang Y,
    6. Zhang S,
    7. et al.

    (2014) Factors predicting malignancy in patients with polymyositis and dermatomyostis:a systematic review and meta-analysis. PLoS One 9:e94128.

    OpenUrlCrossRefPubMed
16. ↵
    1. Leatham H,
    2. Schadt C,
    3. Chisolm S,
    4. Fretwell D,
    5. Chung L,
    6. Callen JP,
    7. et al.

    (2018) Evidence supports blind screening for internal malignancy in dermatomyositis:Data from 2 large US dermatology cohorts. Medicine (Baltimore) 97:e9639.

    OpenUrl
17. ↵
    1. Oeffinger KC,
    2. Fontham ET,
    3. Etzioni R,
    4. Herzig A,
    5. Michaelson JS,
    6. Shih YC,
    7. et al.

    (2015) Breast Cancer Screening for Women at Average Risk:2015 Guideline Update From the American Cancer Society. JAMA 314:1599–1614.

    OpenUrlCrossRefPubMed
18. ↵
    1. Hendren E,
    2. Vinik O,
    3. Faragalla H,
    4. Haq R

    (2017) Breast cancer and dermatomyositis:a case study and literature review. Curr Oncol 24:e429–e433.

    OpenUrl
19. ↵
    1. Asiri S,
    2. Asiri A,
    3. Ulahannan S,
    4. Alanazi M,
    5. Humran A,
    6. Hummadi A

    (2020) Incidence Rates of Breast Cancer by Age and Tumor Characteristics Among Saudi Women:Recent Trends. Cureus 12:e6664.

    OpenUrl
20. ↵
    1. Woo JH,
    2. Kim YJ,
    3. Kim JJ,
    4. Choi CB,
    5. Sung YK,
    6. Kim TH,
    7. et al.

    (2013) Mortality factors in idiopathic inflammatory myopathy:focusing on malignancy and interstitial lung disease. Mod Rheumatol 23:503–508.

    OpenUrl
21. ↵
    1. Xiao Y,
    2. Zuo X,
    3. You Y,
    4. Luo H,
    5. Duan L,
    6. Zhang W,
    7. et al.

    (2016) Investigation into the cause of mortality in 49 cases of idiopathic inflammatory myopathy:A single center study. Exp Ther Med 11:885–889.

    OpenUrl